A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 x2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 May 2013
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Migraine; Multiple sclerosis; Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- 25 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 May 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 19 Nov 2010 New trial record